Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | CCR5 | P51681 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | HPD | P32754 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884770 | 0.82 | MAOB (0.45) | MAOBMAOACCR5NPC1HTT | |
| SCHEMBL2888058 | 0.82 | MAOB (0.45) | MAOBMAOACCR5NPC1HTT | |
| SCHEMBL2889943 | 0.80 | CCR5 (0.44) | MAOBMAOACCR5NPC1HTT | |
| SCHEMBL1668610 | 0.73 | CCR5 (0.58) | CCR5HTTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL6700872 | 0.72 | MAOB (0.47) | MAOBMAOACCR5SMN1; SMN2XDH | |
| SCHEMBL13384688 | 0.69 | HTR2A (0.46) | MAOBMAOAHTTSMN1; SMN2LMNA | |
| SCHEMBL2888586 | 0.68 | MAPT (0.49) | MAOBMAOACCR5NPC1RAB9A | |
| SCHEMBL22918085 | 0.68 | KDM1A (0.43) | MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL29660949 | 0.68 | KDM1A (0.43) | MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL6932494 | 0.66 | MAOB (0.49) | MAOBMAOANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705043-B2 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7705043-B2 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7705043-B2 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20040082798-A1 | Novel amino dicarboxylic acid derivatives with pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082798-A1 | Novel amino dicarboxylic acid derivatives with pharmaceutical properties | ABAT, BCAT2, GOT1 | MAOB 3358/4885MAOA 2829/4885CCR5 2730/4885 |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | ACMSD, AADAT, DDC | MAOB 924/4885MAOA 975/4885CCR5 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.